GHO Capital Acquires Ardena, a European Early‑Stage CDMO

Ardena (GHO Capital Portfolio) Acquires Idifarma from Suanfarma and Sodena

September 2, 2021

Healthcare Services

Ardena, a GHO Capital-backed specialist pharmaceutical CDMO, has acquired Idifarma from Suanfarma and Sodena. The deal expands Ardena's European footprint and adds Idifarma's spray drying technology and high-potency drug capabilities at its Pamplona site, supporting Ardena's integrated end-to-end CDMO strategy.

Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility

October 14, 2024

Pharmaceuticals

Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

Astorg Acquires Pharmaceutical CDMO CordenPharma from ICIG

May 2, 2022

Pharmaceuticals

Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.

GHO Capital Invests in RoslinCT

January 11, 2022

Biotechnology

GHO Capital Partners LLP has made a growth equity investment in RoslinCT, a UK-based contract development and manufacturing organisation (CDMO) focused on advanced cell therapies. The capital will support scaling of RoslinCT’s cGMP manufacturing capacity, international customer acquisition and product diversification to drive commercial-scale cell therapy manufacturing.

GHO Capital Leads Consortium to Acquire Majority Stake in Envision Pharma Group from Ardian

November 5, 2020

Healthcare Services

GHO Capital Partners, leading a consortium that includes Mubadala Investment Company, HarbourVest Partners and Northwestern Mutual, together with Envision management and employees, has acquired a majority stake in Envision Pharma Group as Ardian exits its investment. The transaction will support Envision's continued growth, wider rollout of its iEnvision medical affairs platform and strategic acquisitions to expand its medical affairs, communications and technology capabilities.